Look back at pharma news in the week to September 24, 2021 September 27, 2021

26 September 2021

By Barbara Obstoj-Cardwell

News in the past week saw the US Food and Drug Administration announcing a number of significant approvals. First, an FDA advisory committee voted to limit booster COVID-19 jabs with Pfizer/BioNTech’s Comirnaty only for older and at-risk people, that was later countered by a different decision from the CDC. Also, Denmark’s Genmab and US biotech Seagen gained FDA approval for their cervical cancer drug Tivdak (tisotumab vedotin). US biotech Incyte received FDA backing for Opzelura, its topical formulation of Jakafi, for the treatment of atopic dermatitis. And Incyte also received an additional approval form the US regulator for its top-selling drug Jakafi for chronic graft-versus -host disease. Also of note, French ophthalmology specialist Nicox announced negative results from a mid-stage trial of its NCX-4251 in the treatment of blepharitis.

Narrowed VRBPAC vote for Pfizer/BioNTech highlights limits of booster opportunity for Moderna

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK